New frontiers for rare pulmonary diseases

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Agostini, Carlo ^a   Harari, Sergio ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

Bosentan; Idiopathic pulmonary fibrosis; Interferon gamma 1b; Lymphangioleiomyomatosis; N Acetylcysteine; NSIP; Pirfenidone; Pulmonary arterial hypertension; Sildenafil; UIP

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; CYCLOPHOSPHAMIDE; ENDOTHELIN 1; GAMMA1B INTERFERON; NEW DRUG; PIRFENIDONE; PREDNISONE; SILDENAFIL;

CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; DISEASE CLASSIFICATION; HUMAN; IDIOPATHIC DISEASE; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS PROTEINOSIS; LUNG DISEASE; LUNG FUNCTION; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE;

ALVEOLITIS, EXTRINSIC ALLERGIC; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ITALY; LUNG DISEASES, INTERSTITIAL; MALE; PREVALENCE; PROGNOSIS; RARE DISEASES; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SURVIVAL RATE;

EID: 31544474897     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Xaubet A, Ancochea J, Morell F, et al: Report of the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 64-70.
2. Katzenstein A, Fiorelli R: Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-47.
3. Nakamura Y, Chida K, Suda T, et al: Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 235-41.
4. Selman M, Pardo A: Idiopathic pulmonary fibrosis: misunderstandings between epithelial cells and fibroblasts? Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 165-72.
5. Beeh K, Beier J, Kornmann O, Buhl R: Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 138-43.
6. King T, Costabel U, Cordier J, et al: Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Resp Crit Care Med 2000; 161: 646-64.
7. Agostini C: Tailoring immunosuppressive therapy in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 3-9.
8. Azuma A, Nukiwa T, Tsuboi E, et al: Double blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005 (in press).
9. Raghu G, Brown K, Williamson Z, et al: A placebo-controlled trial of interferon gamma 1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33.
10. Dorfmuller P, Humbert M, Capron F, Muller K: Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 9-19.
11. Taveira-DaSilva A, Stylianou M, Hedin C, Hathaway O, Moss J: Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-74.
12. Triggiani M, Granata F, Giannattasio G, et al: Lung involvement in rheumatoid arthritis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 171-9.